Pramana
We address the ripple effect of Metabolic Dysregulation
Pipeline
Improving lives targeting a new mechanism of action to treat metabolic dysregulation via an immune response.
Diabetes & Obesity
One person dies from Diabetes and its complications every eight seconds and Obesity is the cause of nearly 1 out of 5 adult deaths Over 40% of the U.S. population is living with Obesity and minority group members are disproportionally impacted In the US with fewer than 3% being pharmacologically treated for Obesity. The economic impact associated with Obesity is over $1 trillion dollars. We are advancing a
novel combination oral undisclosed therapy in Obesity with a superior target product profile. We are driving transformative solutions for patients.
PRM A
LADA
Hypoglycemia
It is estimated that over 100 million people living with Diabetes have Latent Autoimmune Diabetes (LADA). LADA is often misdiagnosed as T2D and is often referred to as Type 1.5 DIabetes. Hypoglycemia is a recurring problem in 90% of T1D patients and 25% of T2DM patients. Severe hypoglycemia can lead to death. There is no preventative treatment. PRM A has shown significant and differentiating glucagon response. PRM A acts as a smart modulator that auto-adjusts sugar levels in the blood to achieve glycemic control by targeting a specific receptor. PRM A is advancing a novel therapeutic application to treat LADA.
NASH
Our R&D focus for liver and metabolic disease is NASH. Among the largest unmet medical needs globally, NASH and metabolic diseases represent a leading cause of morbidity and mortality and a significant burden for patients and healthcare systems. In the U.S. the annual cost burden is $103 billion and projected to exceed $1 trillion within 10 years. We are advancing a novel once a day oral therapy with a target product profile that is expected to offer a better solution for patients.
Pramana